LITTLETON, Mass., Nov. 1, 2016 /PRNewswire/ -- Amorsa Therapeutics, a neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders, is pleased to announce today that Anita Gupta, D.O., Pharm.D., has been appointed to Amorsa's Board of Directors. "We are extremely proud to welcome Anita to our Board," said Joe Blanchard, President and Chief Executive Officer of Amorsa. "Anita's contributions to the field have been instrumental to the continued advancement of improved treatment options for neurological diseases. Her extensive drug development experience, along with her broad regulatory, clinical, and strategic insight will be invaluable to Amorsa." Dr. Gupta is a board-certified anesthesiologist, pain specialist, pharmacist and author of top-selling books including Interventional Pain Medicine (2012) and Pharmacology in Anesthesia Practice (2013). For nearly two decades, Dr. Gupta has lead visionary research efforts to advance the field of pain medicine and has served as a medical consultant with numerous drug development companies and healthcare providers. As a recognized international authority in pain medicine, she is regularly called on to discuss breaking medical news on CNN, Forbes, Fox News, NBC and other news outlets. In addition, she currently serves as an advisor to the FDA as a member of the Anesthetic and Analgesic Drug Products Advisory Committee. Dr. Gupta received her Doctorate in Pharmacy from Rutgers University, her medical degree from the University of Medicine and Dentistry of New Jersey and completed a combined residency in anesthesiology and research at Georgetown University Hospital and the National Institutes of Health, respectively. Following her residency, Dr. Gupta completed a pain management fellowship at Johns Hopkins University. About Amorsa Therapeutics Amorsa is an early-stage, neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders including moderate-to-severe pain and treatment-resistant depression. Founded in 2013, Amorsa has assembled a leadership team that helped build several life science companies and has a highly successful track record in developing novel therapeutic treatments. In addition, Amorsa has attracted leading neuroscience and pain management experts to join its Scientific and Clinical Advisory Board.